Prostate cancer not likely to be cause of death in men with low-risk disease
the ONA take:
Relatively unaggressive prostate tumors are not likely to develop into metastatic disease or result in death, according to a study by researchers at the Brady Urological Institute at Johns Hopkins.
The researchers analyzed survival data of 1,298 men enrolled over the past 20 years in an active surveillance program Johns Hopkins. Of the participants, just two men died of prostate cancer, and three developed metastatic disease.
Urologists carefully selected which men were candidates for active surveillance and monitored the participants. Selection was based, in part, on Gleason scores determined by pathologic evaluation of prostate biopsy tissue.
In 1995, when the study began, the men underwent annual biopsy until age 75 years. Annual biopsies are no longer required among those men in the lowest risk group; however, when a biopsy is performed, MRI-guided technology is used and pathologists are asked to check biopsy tissue levels of proteins made by the PTEN gene, a biomarker for prostate cancer aggressiveness.
A benefit of using active surveillance for men who prostate cancer is very low or low-risk is reduction in rates of complications and costs of prostate cancer treatments.
Relatively unaggressive prostate tumors are not likely to develop into metastatic disease or result in death.
Sign Up for Free e-newsletters
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Endocrine Society Released Guidelines for Managing Endocrine Disorders in Childhood Cancer Survivors
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|